Surgical therapy of peri-implantitis lesions by means of bovine-derived xenograft. Comparative results of a prospective study on two different implant surfaces.

Mario Roccuzzo, Francesca Bonino, Luca Bonino, Paola Dalmasso

To cite this version:


HAL Id: hal-00647405
https://hal.science/hal-00647405
Submitted on 2 Dec 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Surgical therapy of peri-implantitis lesions by means of bovine-derived xenograft. Comparative results of a prospective study on two different implant surfaces.

<table>
<thead>
<tr>
<th>Journal:</th>
<th><em>Journal of Clinical Periodontology</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID:</td>
<td>CPE-12-10-3012.R2</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Original Article Implant Dentistry</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>02-Apr-2011</td>
</tr>
<tr>
<td>Complete List of Authors:</td>
<td>Roccuzzo, Mario; Private Practice</td>
</tr>
<tr>
<td></td>
<td>Bonino, Francesca; Private Practice</td>
</tr>
<tr>
<td></td>
<td>Bonino, Luca; Private Practice</td>
</tr>
<tr>
<td></td>
<td>Dalmasso, Paola; University of Torino, Public Health and Microbiology</td>
</tr>
<tr>
<td>Topic:</td>
<td>Implantology</td>
</tr>
<tr>
<td>Keywords:</td>
<td>per-implantitis, surgical treatment, defect fill, bone substitute, surface decontamination</td>
</tr>
<tr>
<td>Main Methodology:</td>
<td>Clinical Trial</td>
</tr>
</tbody>
</table>
Surgical therapy of peri-implantitis lesions by means of bovine-derived xenograft.

Comparative results of a prospective study on two different implant surfaces.

Authors:

Mario Roccuzzo: Private practice, Torino; University of Torino, Department of Maxillo-facial Surgery.

Francesca Bonino: Private practice, Torino.

Luca Bonino: Private practice, Torino.

Paola Dalmasso; University of Torino, Department of Public Health and Microbiology.

Running header of the manuscript: Surgical treatment of peri-implantitis

Corresponding author:

Mario Roccuzzo, D.D.S.

Corso Tassoni, 14

10143 Torino

Italy

mroccuzzo@iol.it

Key words:

Bone substitute; Biomaterial; Peri-implantitis; Defect fill; Surgical treatment.
Abstract

Objectives: The aim of this prospective study was to evaluate a regenerative surgical treatment modality for peri-implantitis lesions on two different implant surfaces.

Material and Methods: Twenty-six patients with one crater-like defect, around either TPS (Control) or SLA (Test) dental implants, with a probing depth ≥ 6mm and no implant mobility, were included. Implant surface was mechanically debrided and treated using 24% EDTA gel and 1% Chlorhexidine gel. The bone defect was filled with bovine-derived xenograft (BDX) and the flap was sutured around the non-submerged implant.

Results: One-year follow-up demonstrated clinical and radiographic improvements. Probing depth were significantly reduced by 2.1 ± 1.2 mm in Control and by 3.4 ± 1.7 mm in Test. Complete defect fill was never found around Controls, while occurred in 3 out of 12 Test implants. Bleeding on probing decreased from 91.1 ± 12.4% (Control) and 75.0 ± 30.2% (Test) to 57.1 ± 38.5% (p=0.004) and 14.6 ± 16.7% (p=0.003) respectively. Several deep pockets (≥ 6mm) were still present after surgical therapy around Controls.

Conclusions: Surface characteristics may have an impact on the clinical outcome following surgical debridement, disinfection of the contaminated surfaces and grafting with BDX. Complete fill of the bony defect seems not to be a predictable result.

Conflict of interest and source of funding statement

The authors declare that they have no conflict of interests in this study. The study was self-funded; no external funding was available for this research.

Mario Roccuzzo received grants and travel funds from Institut Straumann AG and Geistlich Pharma AG
Clinical Relevance

Scientific rationale for the study: In animal studies the treatment of peri-implantitis is influenced by the surface characteristics of the implants. Limited information on the regenerative possibilities in peri-implantitis lesions around implants of different surfaces is available on humans. The objective of this clinical trial is to test the efficiency of a surgical protocol in defects around TPS and SLA implants.

Principal findings: Surgical regenerative treatment by means of BDX resulted in clinical and radiographic significant improvements after 1 year, particularly around SLA implants. Complete fill of the bony defect seems not to be a predictable outcome.

Practical implications: Surface characteristics might be considered as a clinical parameter potentially influencing the outcome following surgical regenerative therapy of peri-implantitis lesions after decontamination of implants and grafting with BDX. These preliminary results provide an ethical base to perform randomized controlled clinical studies to investigate various methods for the decontamination of implant surfaces and grafting materials. In the meantime, the clinical decision on whether implants should be removed or treated by means of decontamination and regenerative procedure may be based on several factors, including surface characteristics.
INTRODUCTION


Various protocols have been suggested in the treatment of peri-implantitis. Non-surgical procedures alone, however, appear to be insufficient to resolve peri-implantitis lesions (Renvert et al. 2008), while surgical procedures may promote access for removal of bacteria on the implant surface. Nevertheless, Claffey et al. (2008), reported that data obtained from case series and animal experiments indicate that no single cleaning method including chemical agents used during surgical treatment of peri-implantitis was proven to be superior.

The outcome of surgical treatment of peri-implantitis at implants with different types of surfaces has been evaluated in animal experiments. Persson et al. (2001) reported that resolution occurred following surgical treatment at implants with both smooth and SLA surfaces. Parlar et al. (2009), showed that treatment of peri-implantitis with decontamination method resulted in considerable more bone fill around an SLA implant than TPS. More recently, Albouy et al. (2011) demonstrated that resolution of peri-implantitis following surgical treatment is possible but the outcome of treatment is influenced by implant surface characteristics.

Two systematic reviews based on RCTs (Kotsovilis et al. 2008, Esposito et al. 2010) failed, however, to determine which is the most effective way to treat peri-implantitis. Apart from surface decontamination, it seems useful, in crater-formed defects, to correct the anatomical conditions for improving plaque control and for eliminating the favourable environment for anaerobic bacteria by means of bone regenerative procedures (Schwarz et al. 2010). The most recent literature research on the matter, to the best of our knowledge, (Sahrmann et al. 2011) aimed to assess available literature for regenerative treatment using bone-graft substitutes and membranes. A large heterogeneity concerning disinfection protocols and regenerative materials used and the high percentage of low-quality studies rendered a meta-analysis impossible. Well-controlled trials are needed to determine predictable protocols for the successful treatment of peri-implantitis using GBR technique.

The aim of this prospective study was to evaluate and compare the healing, following regenerative surgery, after decontamination of implants, by means of bovine-derived xenograft, in defects around implants of 2 different surfaces.

**MATERIALS AND METHODS**

**Patient Population**

From January 2008 to June 2009, twenty-six patients (10 males and 16 females; mean age: $60 \pm 7.9$ years; 4 smokers), who presented a peri-implantitis crater-like lesion with a probing depth (PD) of $> 6\text{mm}$ and no implant mobility, were consecutively enrolled from those attending the principle investigator’s private practice. The specialist practice receives referrals from general dental practitioners, specialists in orthodontics, specialists in maxillo-facial surgery and physicians, mainly located in the North-west of Italy.

Patients had been treated, in the previous years, for periodontitis and subsequently had
received therapy by means of dental implants of 2 different surfaces, i.e.: Titanium Plasma-sprayed Surface (TPS) and Sand blasted Large grit and Acid etched surface (SLA) (Straumann Dental Implant System, Straumann AG, Basel, Switzerland). All implants supported cemented fixed dental prostheses only. Patients had been recalled at various intervals, depending on the initial diagnosis and the results of the therapy, for supporting periodontal therapy (SPT). Motivation, reinstruction, instrumentation and treatment of re-infected sites were performed as needed. Patients had been placed on an individually tailored maintenance care program, including continuous evaluation of the occurrence and the risk of disease progression.

All patients had complied with the recall program until evaluation of the peri-implantitis. Hollow cylinder and hollow screws implants were not included in the study. Only one implant defect per patient was included in the study (Table 1). The baseline demographic and clinical characteristics of the patients, divided in 2 groups according to the implant surface, are represented in Table 2. Each patient was given a detailed description of the procedure. They were also informed that their data would be used for statistical analysis and gave their informed consent to the treatment. No ethical committee approval was sought to start up this observational study, as it was not required by national law or by ordinance of local inspective authority. The prospective study was performed in accordance with the principles stated in the Declaration of Helsinki and the Good Clinical Practice Guidelines.

Surgical procedures.

Each patient underwent scaling and root planing and professional implant cleaning after receiving personalized oral hygiene instructions. No surgery was performed before the reassurance of good motivation and compliance from each single patient, Full-mouth plaque
score (FMPS) < 20% and Full-mouth bleeding score (FMBS) < 20%.

All surgeries were performed by one surgeon (MR) with 20 year of experience in periodontal surgery. The area selected for surgery was anesthetized with mepivacaine plus epinephrine 1:100,000. Full-thickness, mucoperiosteal flaps were raised by means of intracrevicular incisions. Subsequently, all granulation tissue was completely removed from the defect area and the implant surfaces were thoroughly debrided using plastic curettes (Straumann AG, Basel, Switzerland). Following cleaning, the exposed implant was covered with EDTA 24% (Prefgel Straumann AG, Basel, Switzerland) for 2 minutes and Chlorhexidine 1% gel (Corsodyl dental gel, GlaxoSmithKline, Baranzate, Italy) for 2 minutes. Then the implant and bony surfaces were thoroughly rinsed with sterile physiologic saline. Bovine-derived xenograft (BDX) (BioOss® Collagen, Geistlich, Wolhusen, Switzerland) was applied in a way as to homogeneously fill the intrabony defect component. Before its application, the graft material was moistened in sterile saline. If the area was with no keratinized tissue, following grafting, a connective tissue graft was trimmed and adapted over the entire defect so as to cover 2–3 mm of the surrounding alveolar bone and to ensure stability of the graft material. Finally, the flap was repositioned coronally and fixed with sutures to ensure a non-submerged healing procedure.

**Postsurgical Care**

Patients were instructed to take 1 g of Amoxicillin and Clavulanic acid twice a day for 6 days, starting at least 1 hour prior to surgery, and non-steroidal analgesics, as needed. Immediately after surgery, the patients applied ice packs at the treated area, and it was recommended that these be kept in place for at least 4 hours. Patients were advised to discontinue tooth brushing and to avoid trauma at the site of surgery for 3 weeks. They were also instructed to
use 0.2% chlorhexidine digluconate rinse for 1 minute 3 times a day for the same period of time. Patients were seen after 7 days and then weekly for the first month to monitor healing. The sutures were removed after 14 days. After the healing phase, patients were placed on an individually tailored maintenance care program. Motivation, reinstruction, supragingival instrumentation and antiseptic therapy were performed as needed.

**Clinical Assessments**

The outcome variables for this study were probing depth reduction (PD), bleeding on probing (BOP) reduction, and bone defect (BD) fill.

Immediately before surgery and 12 months postoperatively, a calibrated examiner (FB), blinded to the initial classification of the patients, collected the following parameters by means of a periodontal probe (XP23/UNC 15, Hu-Friedy, Chicago, IL): Probing depth (PD) according to Fiorellini and Weber (1994) at the mesial, distal, buccal, and palatal/lingual aspects of each implant. At the same time and sites the presence of dental plaque (Pl), of bleeding on probing (BOP) and of pus were recorded. Figures were rounded off to the nearest millimeter. At the same time, the distance between the base of the implant shoulder and the most coronal visible bone-to-implant contact (BL) measured in millimetres, both at the mesial and the distal aspect of each implant, was collected using standardized periapical intraoral films with a long cone technique (Roccuzzo et al. 2001; Bornstein et al. 2005). The 12-month BL values were compared with the baseline values according to the technique previously described by Roccuzzo et al. (2008) and the radiographic bone-defect (BD) fill was calculated.

**Statistical Analysis**

Each patient contributed with one peri-implantitis lesion and was, therefore, regarded as the
statistical unit. Data were expressed as mean ± SD or percentages. The statistical distribution of the quantitative measures was found to be non-gaussian (Shapiro-Wilk test) and non-parametric tests were used. Comparison between the 2 groups was performed by means of Fisher’s exact test for qualitative variables, and the Mann-Whitney rank-sum tests for quantitative variables. Pre- and post-surgery recordings were conducted using exact McNemar test or Wilcoxon matched-pairs signed-rank test. All the tests were two tailed. The level of significance was set at 5%.

RESULTS

In all patients, surgery and immediate healing proceeded without complications and with minimal postoperative discomfort. No patient dropout and no implant removal were registered during the first 12 months of observation. The clinical parameters in both groups at baseline and at 1-year evaluation are summarized in Table 2-4.

In control group, PD decreased from 7.2 ± 1.5 mm to 5.1 ± 2.0 mm, corresponding to a statistically significant reduction of 2.1 ± 1.2 mm (p=0.001). In test group, PD decreased from 6.8 ± 1.2 mm to 3.4 ± 1.0 mm, corresponding to a statistically significant reduction of 3.4 ± 1.7 mm (p=0.003). A statistically significant difference in PD reduction was found between the 2 groups (p=0.04)

Controls presented on average 3.1 ± 1.1 sites per patient with PD ≥ 6mm at baseline and 1.2 ± 1.7 sites at 1 year (p=0.002). Test implants presented 2.8 ± 1.1 mean sites per patient with PD ≥ 6 mm at baseline, which all disappeared at 1-year evaluation (p=0.002). Even though the reduction was greater in Test, the difference between the 2 groups did not reach the statistically significant level.
At baseline BOP was present around 91.1 ± 12.4% of the control and 75.0 ± 30.2% of test implant sites. At 1-year examination, the values significantly decreased to 57.1 ± 38.5% (p=0.004) and to 14.6 ± 16.7% (p=0.003), respectively. The difference between the 2 groups was statistically significant (p=0.007).

In control, mean BL decreased from 3.9 ± 1.6 mm to 2.2 ± 1.3 mm, corresponding to a reduction of 1.6 ± 0.7 mm (p=0.001). In test, BL decreased from 3.0 ± 0.9 mm to 1.1 ± 0.8 mm, corresponding to a reduction of 1.9 ± 1.3 mm (p=0.002). Both reductions were statistically significant, but the difference between the 2 groups were not statistically significant. Complete bone defect fill was never found in control, while occurred in 3 out of 12 in test. However, no statistical significant difference between the two groups was detected.

At baseline, plaque was found around 64.3 ± 25.4% of control and 45.8% ± 25.7% of test implants. At 1-year examination plaque was present around 30.4 ± 24.4% (p=0.003) and 16.7 ± 16.3% (p=0.01), respectively. The reduction was statistically significant in both groups. The difference between test and control, however, did not reach a statistically significant level.

Before treatment, pus was present around 10 implants of Control and 4 of Test. At the end of the observation period, all test implants healed, while 4 of control did not. After the 1 year examination, 2 of these 4 TPS implants presented deep pockets with pus and were subsequently removed.

**DISCUSSION**

The aim of this prospective study was to evaluate the results of regenerative surgery by means of BDX in peri-implant defects around implants of 2 different surfaces. The outcome variables were probing depth reduction (PD), bleeding on probing (BOP) reduction, and bone defect (BD) fill.
The proposed treatment was effective in reducing the mean pocket depth, even though it produced better results in the test group. In particular, mean PD decrease was \(2.1 \pm 1.2\) mm in control and \(3.4 \pm 1.7\) mm in test, with a statistically significant difference between the groups \((p=0.04)\). No deep pockets \((PD \geq 6\text{mm})\) were detected in test at the end of the observation period, while \(1.2 \pm 1.7\) mean sites were still present in control. From a clinical point of view, this result seem quite interesting, even though the difference did not reach a statistically significant level, probably due to the small sample size of the two groups. It is not possible to draw definitive conclusions, but these positive preliminary results encourage further investigation with a similar protocol.

The surgical therapy was also effective in reducing the proximal bone defects, especially in Test. In particular, complete defect fill occurred around 25% of the SLA implants while it was never found around TPS implants. The mean defect fill (measured mesially and distally at each implant) was \(1.6 \pm 0.7\) mm in control and \(1.9 \pm 1.3\) mm in test, with a difference which did not reach a significant level. Two TPS implants out of 14 were removed, at the end of the follow-up period, as a consequence of the persistence of deep pockets.

Behneke et al. (2000) presented a report on 25 ITI screw implants in 17 patients, with air-polishing of the surface, and corticocancellous bone grafts or particulate bone placed into the peri-implant osseous defects, allowing transmucosal healing. Two of the 25 cases resulted in a negative outcome of the procedure. The results of this study suggested that the use of autogenous bone grafts appears to be an efficacious treatment approach for restoring the bone loss caused by peri-implantitis. The success of the treatment was attributed to the use of autogenous bone as an augmentation material with the possibility of maintenance of cellular viability and rapid revascularization. It must be said, however, that the possibility of placement of a block into a defect depends on the morphology of the defect and may be quite difficult in
some anatomic circumstances. On the other hand, the spongy consistency of BDX Collagen, used in the present study after moistening in sterile saline, allowed simple trimming and easy adaptation of the material to the peri-implant defects.

Khoury & Buchmann (2001) concluded that submerged healing of autogenous bone grafts, with and without the application of barriers, in advanced peri-implant disease represents an appropriate treatment regimen to augment the open crater-deformed defects, and is significantly associated with a long-term stability of peri-implant health. The advantages of the technique presented in the present study is that healing seems to be present without the need of the removal of the prosthetic restoration in order to submerge the implant reducing time and cost of treatment. It must be said, however, that a minimal amount of keratinized tissue was considered necessary for a successful application of the technique. Therefore, in areas with no keratinized mucosa, a connective tissue graft was trimmed and adapted to ensure stability of the graft material. Test and Control were, with the adopted technique, similar in all aspects, except for implant surface. This was particularly interesting from a statistical point of view, as bias and variability were reduced to minimal levels. It would be useful in the future, to assess if the quality of the soft tissue, i.e. keratinized tissue vs. alveolar mucosa, may influence the treatment outcomes of peri-implantitis, as previous studies have not taken this parameter into careful consideration.

Leonhardt et al. (2003) treated 26 implants demonstrating peri-implantitis in 9 periodontally compromised partially dentate individuals (5 smokers) by means of surgical exposure of the lesions and cleaning using hydrogen peroxide. No attempt to regenerate the bone defect was pursued, while antibiotic regimen was started according to a susceptibility test of target bacteria. The treatment was successful in 58% of the implants treated during the 5-year follow-up period. Smoking seemed to be a negative factor for treatment success.
contrary Serino & Turri (2011) found no difference in the mean number of implants with peri-
implantitis at the 2-year examination between smokers and non-smokers. In the present study
the number of smokers was so limited (4 out of 26) to draw any conclusions.

The question if submerged healing and/or the application of a membrane may have resulted
in more pronounced bone defect fill is still open. Roos-Jansåker (2007b) presented one study
on regenerative surgical treatment modality for peri-implantitis employing submerged healing
in 12 patients. After surgical exposure of the defect the implant surface was treated using 3%
hydrogen peroxide. The bone defects were filled with a bone substitute and a resorbable
membrane was placed over the grafted defect. The implant was then covered by flaps and
submerged healing was allowed for 6 months. Probing depth was reduced by 4.2 mm and a
mean defect fill of 2.3 mm was obtained. In the same year, the same author Roos-Jansåker
(2007a) presented a prospective cohort study using a bone substitute with or without
resorbable membranes punched and fixed over the implant by the abutment. There was no
significant difference between the 2 groups. No sufficient data are present to leap to definitive
conclusions on this matter. In the present study it was decided not to use the membrane in
order to keep the procedure as simple as possible in agreement with data showing that the
placement of Bio-Oss Collagen alone in fresh extraction sockets may counteract
postextraction ridge reductions (Araújo & Lindhe 2009). More recently, Araújo et al. (2011)
demonstrated that the placement of Bio-Oss Collagen in the void between the implant and the
buccal-approximal bone walls of fresh extraction sockets provided additional amounts of hard
tissue at the entrance of the previous socket and improved the level of marginal bone-to-
implant contact.

A similar protocol, without the use of a membrane, was recently described by Wiltfang et al.
(2010), who presented the results in 36 cases of peri-implantitis-induced bone loss (depth > 4
mm) that were followed for 1 year. The implants were decontaminated with etching gel and
the defects were filled with autologous bone mixed 1:1 with a xenogenic bone graft. The
bone defects after treatment revealed a mean reduction of 3.5 mm comparing the values from
5.1 mm prior to surgery to 1.6 mm 1 year after treatment. Average reduction of the probing
depth was 4 mm. Probing depths of more than 4 mm were present in seven implants.

Regarding BOP, at baseline, bleeding was found at 91.1 ± 12.4% of the sites compared with
57.1 ± 38.5% after treatment (p=0.004), in control and at 75.0 ± 30.2% of the sites
compared with 14.6 ± 16.7% after treatment (p=0.003), in test. The improved bleeding
scores for both groups indicate a clinically healthier situation after therapy in accordance with
Lang et al. (1990) and Roos-Jansåker et al. (2007a, 2007b).

It is interesting to note that at 1-year evaluation, both FMPS (21.0 ± 6.8 % vs. 19.5 ± 5.2 %)
and FMBS (20.6 ± 6.0 % vs. 18.6 ± 6.1 %) were reduced to an acceptable level with no
statistical difference between the two groups. This may indeed suggest that the study
outcome is not related to oral hygiene but somehow to implant surface characteristics.

The question about the ideal protocol for bactericidal effect against adhering bacteria is still
open. Schou et al. (2003) indicated that the simplest method involving chlorhexidine and saline
should be the preferred implant surface preparation method. A recent paper by Gosau et al.
(2010) revealed that several antiseptics seemed to be able to reduce the total amount of
microorganisms accumulating on titanium surfaces supporting the additional use of
antibacterial agents in peri-implant therapy. Similarly, Schwarz et al. (2011) failed to
demonstrate a significant impact of the method of surface decontamination on the clinical
outcome following combined surgical therapy of advanced peri-implantitis lesions. The two
step procedure (EDTA + chlorhexidine gel) employed in this research has never been
described before and has been selected because it presents the advantage of low-cost and easy use. Its real efficacy, however, can be confirmed only by controlled bacterial studies. Unlike the studies of Schwarz et al. (2006, 2009) where several implant types and implant surfaces were investigated, this research evaluated the outcome of the same surgical protocol on implants that differ by only one variable of interest, i.e. surface characteristics. While the TPS surface has $S_a$ values of approximately 3.1 $\mu$m, SLA has $S_a$ values of approximately 2.0 $\mu$m (Buser et al. 1999). In a recent systematic review, prepared for the Seventh European Workshop on Periodontology, Renvert et al. (2011) revealed that only a few studies provided data on how implant surfaces influence peri-implant disease, with no evidence that implant surface characteristics can have a significant effect on the initiation of peri-implantitis. In animals, it is demonstrated (Albouy et al. 2011) that resolution of peri-implantitis following surgery is possible and that the outcome of treatment is influenced by implant surface characteristics, but no comparative clinical research has confirmed this difference in humans. The preliminary results of this study seem to confirm data from a recent research on mandibles of dogs (Parlar et al. 2009), where the treatment of peri-implantitis with decontamination method resulted in considerable more bone fill around an SLA implant than TPS. In the clinical practice, of course, the amount of re-osseointegration on previously plaque contaminated surface cannot be evaluated.

In conclusion, the antimicrobial and surgical technique described resulted in a clinical healthier situation around many of the treated implants so that their function could be fully maintained. Moreover, the treatment around SLA implants presented better final results, even though the reason for this is not fully understood. The time in function of the implants varied considerably from 14 to 120 months. The impact of this variable is also completely unknown. Nevertheless, these preliminary results seems to suggest that the clinical decision on whether
implants should be removed or treated may also be based on the surface characteristics. Ideally, this should be established on large well-designed RCTs with long follow-up. Practical and ethical reasons, however, make RCTs possible only after preliminary information, from lower quality studies, are available. Within its limits, mainly the lack of classification of the defects (Schwarz et al. 2010) and the relatively small sample size, the present pilot study represents a step in the definition of the ideal protocol for the treatment of peri-implant defect. Finally, more years of observation are necessary to verify whether an osseous defect fill with incomplete “re-osseointegration” is sufficient to ensure favorable long-term maintenance of the implants.
REFERENCES


Table 1. Data on patients, defect location, implant type, months in function

<table>
<thead>
<tr>
<th>n</th>
<th>SEX</th>
<th>AGE</th>
<th>SMOKING</th>
<th>SITE</th>
<th>IMPLANT TYPE</th>
<th>Months in function</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>56</td>
<td></td>
<td>25</td>
<td>ø 4.1 x 10 mm TPS</td>
<td>80</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>53</td>
<td></td>
<td>31</td>
<td>ø 3.3 x 12 mm TPS</td>
<td>63</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>68</td>
<td></td>
<td>21</td>
<td>ø 4.1 x 10 mm SLA</td>
<td>22</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>66</td>
<td></td>
<td>35</td>
<td>ø 4.1 x 10 mm TPS</td>
<td>98</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>55</td>
<td></td>
<td>46</td>
<td>ø 4.1 x 08 mm SLA</td>
<td>14</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>55</td>
<td></td>
<td>14</td>
<td>ø 4.1 x 10 mm TPS</td>
<td>20</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>60</td>
<td></td>
<td>24</td>
<td>ø 4.1 x 10 mm SLA</td>
<td>58</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>68</td>
<td></td>
<td>27</td>
<td>ø 4.8 x 08 mm SLA</td>
<td>44</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>67</td>
<td></td>
<td>26</td>
<td>ø 4.1 x 10 mm TPS</td>
<td>114</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>58</td>
<td>Yes</td>
<td>13</td>
<td>ø 4.1 x 10 mm SLA</td>
<td>54</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>70</td>
<td></td>
<td>23</td>
<td>ø 4.1 x 08 mm TPS</td>
<td>96</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>56</td>
<td></td>
<td>37</td>
<td>ø 4.8 x 08 mm SLA</td>
<td>69</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>79</td>
<td></td>
<td>35</td>
<td>ø 4.1 x 10 mm TPS</td>
<td>60</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>60</td>
<td></td>
<td>26</td>
<td>ø 4.1 x 10 mm TPS</td>
<td>24</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>54</td>
<td></td>
<td>26</td>
<td>ø 4.1 x 10 mm TPS</td>
<td>58</td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>63</td>
<td></td>
<td>31</td>
<td>ø 4.1 x 10 mm TPS</td>
<td>90</td>
</tr>
<tr>
<td>17</td>
<td>F</td>
<td>46</td>
<td>Yes</td>
<td>17</td>
<td>ø 4.8 x 10 mm SLA</td>
<td>34</td>
</tr>
<tr>
<td>18</td>
<td>M</td>
<td>51</td>
<td>Yes</td>
<td>46</td>
<td>ø 4.1 x 12 mm TPS</td>
<td>49</td>
</tr>
<tr>
<td>19</td>
<td>F</td>
<td>71</td>
<td></td>
<td>17</td>
<td>ø 4.8 x 10 mm SLA</td>
<td>78</td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>64</td>
<td>Yes</td>
<td>35</td>
<td>ø 4.1 x 12 mm TPS</td>
<td>84</td>
</tr>
<tr>
<td>21</td>
<td>F</td>
<td>57</td>
<td></td>
<td>36</td>
<td>ø 4.1 x 08 mm TPS</td>
<td>92</td>
</tr>
<tr>
<td>22</td>
<td>F</td>
<td>56</td>
<td></td>
<td>27</td>
<td>ø 4.1 x 08 mm SLA</td>
<td>54</td>
</tr>
<tr>
<td>23</td>
<td>F</td>
<td>56</td>
<td></td>
<td>14</td>
<td>ø 4.1 x 10 mm SLA</td>
<td>49</td>
</tr>
<tr>
<td>24</td>
<td>F</td>
<td>63</td>
<td></td>
<td>46</td>
<td>ø 4.1 x 10 mm SLA</td>
<td>24</td>
</tr>
<tr>
<td>25</td>
<td>M</td>
<td>45</td>
<td></td>
<td>36</td>
<td>ø 4.1 x 12 mm TPS</td>
<td>120</td>
</tr>
<tr>
<td>26</td>
<td>M</td>
<td>62</td>
<td></td>
<td>36</td>
<td>ø 4.8 x 10 mm SLA</td>
<td>52</td>
</tr>
</tbody>
</table>
Table 2. Baseline demographic and clinical parameters in Control (TPS) N= 14 and in Test (SLA) N=12. Means ± SD; Numbers (%).

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Test</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female (%)</td>
<td>9 (64.3)</td>
<td>7 (58.3)</td>
<td>0.99</td>
</tr>
<tr>
<td>Age</td>
<td>59.9 ± 7.0</td>
<td>60 ± 8.8</td>
<td>0.98</td>
</tr>
<tr>
<td>Smoke (%)</td>
<td>2 (14.3)</td>
<td>2 (16.7)</td>
<td>0.99</td>
</tr>
<tr>
<td>FMPS (%)*</td>
<td>30.5 ± 9.1</td>
<td>27.5 ± 7.5</td>
<td>0.33</td>
</tr>
<tr>
<td>FMBS (%)†</td>
<td>29.4 ± 7.6</td>
<td>26.8 ± 10.4</td>
<td>0.21</td>
</tr>
</tbody>
</table>

* Full-mouth plaque score
† Full-mouth bleeding score
Table 3. Clinical parameters around the implants at baseline and 1 year after treatment in both groups. Means ± SD; Numbers (%).

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Post-op</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Probing depth (mm)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>7.2 ± 1.5</td>
<td>5.1 ± 2.0</td>
<td>0.001</td>
</tr>
<tr>
<td>Test</td>
<td>6.8 ± 1.2</td>
<td>3.4 ± 1.0</td>
<td>0.003</td>
</tr>
<tr>
<td><strong>Number of sites per patient with PD ≥ 6 mm</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>3.1 ± 1.1</td>
<td>1.2 ± 1.7</td>
<td>0.002</td>
</tr>
<tr>
<td>Test</td>
<td>2.8 ± 1.1</td>
<td>0</td>
<td>0.002</td>
</tr>
<tr>
<td><strong>Bone level (mm)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>3.9 ± 1.6</td>
<td>2.2 ± 1.3</td>
<td>0.001</td>
</tr>
<tr>
<td>Test</td>
<td>3.0 ± 0.9</td>
<td>1.1 ± 0.8</td>
<td>0.002</td>
</tr>
<tr>
<td><strong>Bleeding on probing at implant site (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>91.1 ± 12.4</td>
<td>57.1 ± 38.5</td>
<td>0.004</td>
</tr>
<tr>
<td>Test</td>
<td>75 ± 30.2</td>
<td>14.6 ± 16.7</td>
<td>0.003</td>
</tr>
<tr>
<td><strong>Plaque at implant site (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>64.3 ± 25.4</td>
<td>30.4 ± 24.4</td>
<td>0.003</td>
</tr>
<tr>
<td>Test</td>
<td>45.8 ± 25.7</td>
<td>16.7 ± 16.3</td>
<td>0.01</td>
</tr>
<tr>
<td><strong>Pus</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>10 (71.4%)</td>
<td>4 (28.6%)</td>
<td>0.01</td>
</tr>
<tr>
<td>Test</td>
<td>4 (33.3%)</td>
<td>0 (0%)</td>
<td>0.04</td>
</tr>
</tbody>
</table>
Table 4. Results of treatment in both groups. Means ± SD; Numbers (%).

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Test</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Probing Depth Reduction (mm)</td>
<td>2.1 ± 1.2</td>
<td>3.4 ± 1.7</td>
<td>0.04</td>
</tr>
<tr>
<td>Reduction of number of sites per patient with PD ≥ 6 mm</td>
<td>1.9 ± 1.6</td>
<td>2.8 ± 1.1</td>
<td>0.10</td>
</tr>
<tr>
<td>Bone defect fill (mm)</td>
<td>1.6 ± 0.7</td>
<td>1.9 ± 1.3</td>
<td>0.99</td>
</tr>
<tr>
<td>Complete bone defect fill</td>
<td>0 /14 (0%)</td>
<td>3/12 (25%)</td>
<td>0.09</td>
</tr>
<tr>
<td>BOP* reduction</td>
<td>19/56 (33.9%)</td>
<td>29/48 (60.4%)</td>
<td>0.007</td>
</tr>
<tr>
<td>Plaque reduction</td>
<td>19/56 (33.9%)</td>
<td>14/48 (29.1%)</td>
<td>0.59</td>
</tr>
<tr>
<td>Pus elimination</td>
<td>6/10 (60%)</td>
<td>4/4 (100%)</td>
<td>0.25</td>
</tr>
</tbody>
</table>

*Bleeding on Probing
**Figure legends:**

1) Inflammation and pus around the implant, at baseline.
2) Peri-implantitis lesion after removal of granulation tissue and before decontamination of the implant surface.
3) Bovine-derived xenograft applied around the peri-implantitis defect.
4) Non-submerged suture of the flap.
5) Clinical situation and probing around the implant at 1-year follow-up.
Inflammation and pus around the implant, at baseline.

114x76mm (300 x 300 DPI)
127x84mm (300 x 300 DPI)
Bovine-derived xenograft applied around the peri-implant defect.

126x84mm (300 x 300 DPI)
Non-submerged suture of the flap.

139x93mm (300 x 300 DPI)
Clinical situation and probing around the implant at 1-year follow-up.
189x125mm (300 x 300 DPI)